NMTR stock forecast
Our latest prediction for 9 Meters Biopharma Inc's stock price was made on the June 25, 2021 when the stock price was at 1.20$.
In the short term (2weeks), NMTR's stock price should underperform the market by -0.32%. During that period the price should oscillate between -13.21% and +16.27%.
In the medium term (3months), NMTR's stock price should outperform the market by 17.23%. During that period the price should oscillate between -46.86% and +47.76%.
Get email alertsCreate a solid portfolio with NMTR
About 9 Meters Biopharma Inc
9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -0.04$ per share.
The book value per share is -0.23$
Three months stock forecastJune 25, 2021
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2M | -3.40% | -27M | -354.00% | -32M | -0.04 | - | - | 219M | -0.23 | -28M | -3M | -30M |